{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:06:32Z","timestamp":1792667192849,"version":"4.5.0"},"reference-count":95,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003852","name":"Regione Campania","doi-asserted-by":"publisher","award":["SATIN"],"award-info":[{"award-number":["SATIN"]}],"id":[{"id":"10.13039\/501100003852","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015565","name":"Consorzio interuniversitario per le biotecnologie","doi-asserted-by":"publisher","award":["CIB"],"award-info":[{"award-number":["CIB"]}],"id":[{"id":"10.13039\/100015565","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Discimus","award":["Terapia dei tumori ipossici"],"award-info":[{"award-number":["Terapia dei tumori ipossici"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Background: HER2-based retargeted viruses are in advanced phases of preclinical development of breast cancer models. Mesothelin (MSLN) is a cell-surface tumor antigen expressed in different subtypes of breast and non-breast cancer. Its recent identification as a marker of some triple-negative breast tumors renders it an attractive target, presently investigated in clinical trials employing antibody drug conjugates and CAR-T cells. The availability of MSLN-retargeted oncolytic viruses may complement the current immunotherapeutic panel of biological drugs against HER2-negative breast and non-breast tumors. Methods: A fully virulent, tumor-targeted oncolytic Herpes simplex virus-1 (MSLN-THV) with a selectivity for mesothelin-expressing cancer cells was generated. Recombineering technology was used to replace an essential moiety of the viral glycoprotein D with antibody fragments derived from clinically validated MSLN monoclonal antibodies, and to allow IL12 cargo expression in infected cells. Panels of breast and female reproductive system cell lines were used to verify the oncolytic potential of the viral constructs. A platform for production of the retargeted viruses was developed in HEK 293 cells, providing stable expression of a suitable chimeric receptor. Results: We demonstrated the selectivity of viral infection and cytotoxicity by MSLN-retargeted viruses in a panel of mesothelin-positive cancer cells, originating from breast and female reproductive system tumors. We also developed a second-generation oncolytic MSLN-THV, encoding IL12, to enhance the immunotherapeutic potential of the viral backbone. A non-tumor cell line expressing a chimeric MSLN\/Nectin-1 receptor, de-sensitized from antiviral responses by genetic inactivation of the Stimulator of Interferon Genes (STING)-dependent pathway was engineered, to optimize viral yields. Conclusions: Our proof-of-concept study proposes MSLN-retargeted herpesviruses as potential cancer immunotherapeutics for assessments in preclinical models of MSLN-positive tumors, complementing the available panel of oncolytic viruses to HER2-negative breast tumors.<\/jats:p>","DOI":"10.3390\/ijms22020477","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T09:15:16Z","timestamp":1609924516000},"page":"477","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Generation of a Novel Mesothelin-Targeted Oncolytic Herpes Virus and Implemented Strategies for Manufacturing"],"prefix":"10.3390","volume":"22","author":[{"given":"Guendalina","family":"Froechlich","sequence":"first","affiliation":[{"name":"CEINGE Biotecnologie Avanzate S.C.aR.L., Via G. Salvatore 486, 80145 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Gentile","sequence":"additional","affiliation":[{"name":"CEINGE Biotecnologie Avanzate S.C.aR.L., Via G. Salvatore 486, 80145 Naples, Italy"},{"name":"Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universit\u00e0 degli Studi di Napoli Federico II, Via Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigia","family":"Infante","sequence":"additional","affiliation":[{"name":"Nouscom S.R.L., Via di Castel Romano 100, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5761-6178","authenticated-orcid":false,"given":"Carmen","family":"Caiazza","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universit\u00e0 degli Studi di Napoli Federico II, Via Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasqualina","family":"Pagano","sequence":"additional","affiliation":[{"name":"CEINGE Biotecnologie Avanzate S.C.aR.L., Via G. Salvatore 486, 80145 Naples, Italy"},{"name":"Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universit\u00e0 degli Studi di Napoli Federico II, Via Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Scatigna","sequence":"additional","affiliation":[{"name":"CEINGE Biotecnologie Avanzate S.C.aR.L., Via G. Salvatore 486, 80145 Naples, Italy"},{"name":"Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universit\u00e0 degli Studi di Napoli Federico II, Via Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Cotugno","sequence":"additional","affiliation":[{"name":"Nouscom S.R.L., Via di Castel Romano 100, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Morena","family":"D\u2019Alise","sequence":"additional","affiliation":[{"name":"Nouscom S.R.L., Via di Castel Romano 100, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Lahm","sequence":"additional","affiliation":[{"name":"Nouscom S.R.L., Via di Castel Romano 100, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Scarselli","sequence":"additional","affiliation":[{"name":"Nouscom S.R.L., Via di Castel Romano 100, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Nicosia","sequence":"additional","affiliation":[{"name":"CEINGE Biotecnologie Avanzate S.C.aR.L., Via G. Salvatore 486, 80145 Naples, Italy"},{"name":"Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universit\u00e0 degli Studi di Napoli Federico II, Via Pansini 5, 80131 Naples, Italy"},{"name":"Nouscom S.R.L., Via di Castel Romano 100, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Mallardo","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universit\u00e0 degli Studi di Napoli Federico II, Via Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6454-2824","authenticated-orcid":false,"given":"Emanuele","family":"Sasso","sequence":"additional","affiliation":[{"name":"CEINGE Biotecnologie Avanzate S.C.aR.L., Via G. Salvatore 486, 80145 Naples, Italy"},{"name":"Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universit\u00e0 degli Studi di Napoli Federico II, Via Pansini 5, 80131 Naples, Italy"},{"name":"Nouscom S.R.L., Via di Castel Romano 100, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9395-3481","authenticated-orcid":false,"given":"Nicola","family":"Zambrano","sequence":"additional","affiliation":[{"name":"CEINGE Biotecnologie Avanzate S.C.aR.L., Via G. Salvatore 486, 80145 Naples, Italy"},{"name":"Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universit\u00e0 degli Studi di Napoli Federico II, Via Pansini 5, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"101430","DOI":"10.1016\/j.smim.2020.101430","article-title":"New viral vector for infectious diseases and cancer","volume":"50","author":"Sasso","year":"2020","journal-title":"Semin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.omto.2019.04.003","article-title":"Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds","volume":"13","author":"Sivanandam","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","article-title":"Oncolytic viruses as engineering platforms for combination immunotherapy","volume":"18","author":"Pettigrew","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4049\/jimmunol.1701021","article-title":"Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies","volume":"200","author":"Workenhe","year":"2018","journal-title":"J. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1038\/s41598-020-61275-w","article-title":"Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis","volume":"10","author":"Sasso","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_8","first-page":"1060","article-title":"Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies","volume":"10","author":"Sasso","year":"2018","journal-title":"MAbs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy","volume":"4","author":"Rehman","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/mt.2015.115","article-title":"Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses","volume":"23","author":"Woller","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-020-15229-5","article-title":"An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OV.S186337","article-title":"Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development","volume":"9","author":"Jayawardena","year":"2020","journal-title":"Oncolytic Virother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fonc.2017.00202","article-title":"Oncolytic Viruses\u2014Natural and Genetically Engineered Cancer Immunotherapies","volume":"7","author":"Jhawar","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Menotti, L., and Avitabile, E. (2020). Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218310"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10153","DOI":"10.1128\/JVI.01133-08","article-title":"Construction of a Fully Retargeted Herpes Simplex Virus 1 Recombinant Capable of Entering Cells Solely via Human Epidermal Growth Factor Receptor 2","volume":"82","author":"Menotti","year":"2008","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Menotti, L., and Avitabile, E. (2018). HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses. Viruses, 10.","DOI":"10.3390\/v10070352"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.coviro.2016.08.007","article-title":"Retargeting of herpes simplex virus (HSV) vectors","volume":"21","author":"Goins","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/mt.2012.211","article-title":"Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus","volume":"21","author":"Uchida","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1128\/JVI.79.9.5272-5277.2005","article-title":"Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells","volume":"79","author":"Zhou","year":"2005","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Campadelli-Fiume, G., and Petrovic, B. (2016). Retargeting Strategies for Oncolytic Herpes Simplex Viruses. Viruses, 8.","DOI":"10.3390\/v8030063"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.omto.2020.10.006","article-title":"Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment","volume":"19","author":"Cotugno","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.2910500308","article-title":"Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium","volume":"50","author":"Chang","year":"1992","journal-title":"Int. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8751","DOI":"10.1158\/1078-0432.CCR-04-1359","article-title":"Mesothelin: A new target for immunotherapy","volume":"10","author":"Shaw","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"28164","DOI":"10.18632\/oncotarget.4461","article-title":"Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types","volume":"6","author":"Lamberts","year":"2015","journal-title":"Oncotarget"},{"key":"ref_28","first-page":"1741","article-title":"Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer","volume":"19","author":"Inoue","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1073\/pnas.95.2.669","article-title":"Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity","volume":"95","author":"Chowdhury","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1349-7006.2007.00715.x","article-title":"Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells","volume":"99","author":"Sapede","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1158\/1055-9965.EPI-05-0334","article-title":"Mesothelin variant 1 is released from tumor cells as a diagnostic marker","volume":"15","author":"Hellstrom","year":"2006","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.18632\/oncotarget.445","article-title":"Modulating mesothelin shedding to improve therapy","volume":"3","author":"Pastan","year":"2012","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40364-019-0169-8","article-title":"Mesothelin as a biomarker for targeted therapy","volume":"7","author":"Lv","year":"2019","journal-title":"Biomark. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/gt.2015.85","article-title":"Mesothelin-specific cell-based vaccine generates antigen-specific immunity and potent antitumor effects by combining with IL-12 immunomodulator","volume":"23","author":"Chang","year":"2016","journal-title":"Gene Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2018.05.009","article-title":"Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials","volume":"369","author":"Arabi","year":"2018","journal-title":"Exp. Cell Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/1535-7163.MCT-11-0454","article-title":"Mesothelin-targeted agents in clinical trials and in preclinical development","volume":"11","author":"Kelly","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/mt.2011.256","article-title":"Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor","volume":"20","author":"Lanitis","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1158\/1078-0432.CCR-19-2586","article-title":"Phase I\/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma","volume":"26","author":"Alewine","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_41","first-page":"20","article-title":"Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin","volume":"7","author":"Hassan","year":"2007","journal-title":"Cancer Immun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.18632\/oncotarget.2883","article-title":"Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging","volume":"6","author":"Lindenberg","year":"2015","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.3389\/fimmu.2019.01593","article-title":"A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer","volume":"10","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/147323001204000309","article-title":"Clinicopathological significance of mesothelin expression in invasive breast cancer","volume":"40","author":"Wang","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1177\/030006051204000608","article-title":"Mesothelin promotes invasion and metastasis in breast cancer cells","volume":"40","author":"Wang","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/mtm.2016.18","article-title":"Moving oncolytic viruses into the clinic: Clinical-grade production, purification, and characterization of diverse oncolytic viruses","volume":"3","author":"Ungerechts","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Froechlich, G., and Caiazza, C. (2020). Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of Herpes Simplex Oncolytic Virus. Cancers, 12.","DOI":"10.3390\/cancers12113407"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41586-019-1000-2","article-title":"Structural basis of STING binding with and phosphorylation by TBK1","volume":"567","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nature08476","article-title":"STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity","volume":"461","author":"Ishikawa","year":"2009","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature07317","article-title":"STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling","volume":"455","author":"Ishikawa","year":"2008","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature12306","article-title":"cGAS produces a 2\u2032-5\u2032-linked cyclic dinucleotide second messenger that activates STING","volume":"498","author":"Ablasser","year":"2013","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nature12640","article-title":"Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP","volume":"503","author":"Ablasser","year":"2013","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1128\/JVI.02702-13","article-title":"Adenovirus Detection by the cGAS\/STING\/TBK1 DNA Sensing Cascade","volume":"88","author":"Lam","year":"2013","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Ni, G., and Ma, Z. (2018). cGAS and STING: At the intersection of DNA and RNA virus-sensing networks. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007148"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"E2058","DOI":"10.1073\/pnas.1716937115","article-title":"STING-dependent translation inhibition restricts RNA virus replication","volume":"115","author":"Franz","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1038\/srep09928","article-title":"New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41419-019-1711-1","article-title":"Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor","volume":"10","author":"Zhang","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Leshem, Y., and King, E.M. (2018). SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors. Toxins, 10.","DOI":"10.3390\/toxins10110470"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.2147\/OTT.S145105","article-title":"Amatuximab and novel agents targeting mesothelin for solid tumors","volume":"10","author":"Baldo","year":"2017","journal-title":"Onco. Targets Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/9872","article-title":"Improving antibody affinity by mimicking somatic hypermutation in vitro","volume":"17","author":"Chowdhury","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/1743-422X-8-481","article-title":"Herpes simplex virus infects most cell types in vitro: Clues to its success","volume":"8","author":"Karasneh","year":"2011","journal-title":"Virol. J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1158\/1535-7163.MCT-12-0731","article-title":"A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface","volume":"12","author":"Tang","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Chen, Y., and Ayaru, L. (2014). Expansion of anti-mesothelin specific CD4+ and CD8+ T cell responses in patients with pancreatic carcinoma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0088133"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.7150\/jca.18014","article-title":"Plasma Mesothelin as a Novel Diagnostic and Prognostic Biomarker in Colorectal Cancer","volume":"8","author":"Li","year":"2017","journal-title":"J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Leoni, V., and Vannini, A. (2018). A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007209"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"9055","DOI":"10.1158\/0008-5472.CAN-07-0474","article-title":"High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif","volume":"67","author":"Hucl","year":"2007","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Hruz, T., and Laule, O. (2008). Genevestigator v3: A reference expression database for the meta-analysis of transcriptomes. Adv. Bioinform., 420747.","DOI":"10.1155\/2008\/420747"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-020-0198-7","article-title":"The interactions between cGAS-STING pathway and pathogens","volume":"5","author":"Cheng","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e20191422","DOI":"10.1084\/jem.20191422","article-title":"HSV1 VP1-2 deubiquitinates STING to block type I interferon expression and promote brain infection","volume":"217","author":"Bodda","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e02145-17","DOI":"10.1128\/JVI.02145-17","article-title":"Virulent Poxviruses Inhibit DNA Sensing by Preventing STING Activation","volume":"92","author":"Georgana","year":"2018","journal-title":"J. Virol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.chom.2016.01.010","article-title":"The cGAS-STING Defense Pathway and Its Counteraction by Viruses","volume":"19","author":"Ma","year":"2016","journal-title":"Cell Host Microbe"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00430-019-00582-0","article-title":"Coevolution pays off: Herpesviruses have the license to escape the DNA sensing pathway","volume":"208","author":"Stempel","year":"2019","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e00535-17","DOI":"10.1128\/JVI.00535-17","article-title":"Evasion of the STING DNA-Sensing Pathway by VP11\/12 of Herpes Simplex Virus 1","volume":"91","author":"Deschamps","year":"2017","journal-title":"J. Virol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e00841-18","DOI":"10.1128\/JVI.00841-18","article-title":"Herpes Simplex Virus 1 Tegument Protein VP22 Abrogates cGAS\/STING-Mediated Antiviral Innate Immunity","volume":"92","author":"Huang","year":"2018","journal-title":"J. Virol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e01161-18","DOI":"10.1128\/JVI.01161-18","article-title":"Herpes Simplex Virus 1 UL36USP Antagonizes Type I Interferon-Mediated Antiviral Innate Immunity","volume":"92","author":"Yuan","year":"2018","journal-title":"J. Virol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e00099-17","DOI":"10.1128\/JVI.00099-17","article-title":"Evasion of Cytosolic DNA-Stimulated Innate Immune Responses by Herpes Simplex Virus 1","volume":"92","author":"Zheng","year":"2018","journal-title":"J. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e01015-18","DOI":"10.1128\/JVI.01015-18","article-title":"Herpes Simplex Virus 1 \u03b3134.5 Protein Inhibits STING Activation That Restricts Viral Replication","volume":"92","author":"Pan","year":"2018","journal-title":"J. Virol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.it.2017.03.004","article-title":"Evolutionary Origins of cGAS-STING Signaling","volume":"38","author":"Margolis","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.molcel.2015.07.022","article-title":"Ancient Origin of cGAS-STING Reveals Mechanism of Universal 2\u2032,3\u2032 cGAMP Signaling","volume":"59","author":"Kranzusch","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"33123","DOI":"10.1074\/jbc.M112.381756","article-title":"Recognition of mesothelin by the therapeutic antibody MORAb-009: Structural and mechanistic insights","volume":"287","author":"Ma","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1080\/14760584.2017.1394842","article-title":"Chimpanzee adenoviral vectors as vaccines\u2014Challenges to move the technology into the fast lane","volume":"16","author":"Vitelli","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Hall, B.L., and Leronni, D. (2020). Generation of an Oncolytic Herpes Simplex Viral Vector Completely Retargeted to the GDNF Receptor GFR\u03b11 for Specific Infection of Breast Cancer Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228815"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"674920","DOI":"10.1155\/2015\/674920","article-title":"Binding of carbonic anhydrase IX to 45S rDNA genes is prevented by exportin-1 in hypoxic cells","volume":"2015","author":"Sasso","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/s41598-018-37997-3","article-title":"Revealing membrane alteration in cellsoverexpressing CA IX and EGFR by Surface-Enhanced Raman Scattering","volume":"9","author":"Rusciano","year":"2019","journal-title":"Sci Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s42003-020-01464-5","article-title":"Multiple proteases are involved in mesothelin shedding by cancer cells","volume":"1","author":"Liu","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Sasso, E., and Paciello, R. (2015). One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1. Biomed. Res. Int., 703213.","DOI":"10.1155\/2015\/703213"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1099\/jgv.0.000330","article-title":"Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb","volume":"97","author":"Paciello","year":"2016","journal-title":"J. Gen. Virol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1080\/19420862.2018.1463945","article-title":"A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells","volume":"10","author":"Sasso","year":"2018","journal-title":"MAbs"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Ohyama, T., and Takahashi, H. (2020). An NMR-based approach reveals the core structure of the functional domain of SINEUP lncRNAs. Nucleic Acids Res., 48.","DOI":"10.1093\/nar\/gkaa598"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/d41586-020-01404-7","article-title":"The software that powers scientific illustration","volume":"582","author":"Perkel","year":"2020","journal-title":"Nature"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/2\/477\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:07:25Z","timestamp":1760159245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/2\/477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":95,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["ijms22020477"],"URL":"https:\/\/doi.org\/10.3390\/ijms22020477","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]}}}